1. HBW Insight
  2. >>Beauty
  3. >>Policy & Regulation

Honest's Baby Wipes Recall: A Quality-Control Or Preservatives Problem?

 
• By Ryan Nelson

Honest may be finding that its high standards for product quality are hard to meet without traditional preservative workhorses. The company's wipes recall follows a baby powder recall in January, both for potential microbial contamination, which almost inevitably will land Honest on FDA's for-cause inspection list.

Petri dish

The Honest Company, Inc.'s contamination issues that prompted a voluntary baby wipes recall earlier this month may not be traceable to the firm's facilities and manufacturing processes as much as to its "Honestly Made Without" guarantee.

Honest currently is recalling selected lots of its baby wipes – described as "premium plant-based cleansing cloths" – due to the possible presence of mold, which the

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Recalls

More from Policy & Regulation

US Fragrance Firms Should Identify Domestic, Non-Tariff Sources Now – Fragrance House CEO

Firms in the US facing tariff costs should identify US-based, non-tariff sources and lobby local government officials and DC when foreign-sourced ingredients cannot be substituted in the US.

Cosmetics Consortium Shares Studies With FDA To Build Confidence In Animal Testing Alternatives

 
• By Lauren Nardella

By guiding regulators through case studies and mock dossier examples of how to utilize new approach methodologies, the International Collaboration on Cosmetics Safety hopes to counter hesitations in replacing animal tests.

Stakeholders Hope US FDA’s Proposed Animal Test Phase-Out For Drugs Will Extend To OTCs, Cosmetics

 
• By Eileen Francis and Lauren Nardella

The US Food and Drug Administration has released a roadmap to adopt new approach methodologies in lieu of animal testing for monoclonal antibody therapies and other drugs, which may include OTC drugs though the proposal does not specifically include cosmetics.